SECAUCUS, N.J., Jan. 8, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationall ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics, Aimil Ltd., and Dr. Lal PathLabs announce strategic agreement to launch Cardio Diagnostics' PrecisionCHDâ"¢ test in India. ...

As filed with the Securities and Exchange Commission on December 31, 2025 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ASPIRA WOMEN'S HEALTH INC. (Exact name of registrant as specified in its charter) | Delaware | 2835 | 33-0595156 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classificatio ...

Vancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that Mr. James Lavender has joined the BioMark Board of Directors. His appointment follows resolutions accepted during the Company's Annual General Meeting (AGM) held on December 22nd, 2025.Mr. Lavender and his group were major investors in BioMark's ...

Core Viewpoint - Castle Biosciences, Inc. is positioned positively in the market with a price target of $50 set by Canaccord Genuity, indicating a potential upside of 26.77% from its current trading price of $39.44, despite recent insider selling activity [1][6]. Company Performance - The stock opened at $39.44, showing a slight decrease of 0.4%, with a yearly fluctuation between a low of $14.59 and a high of $40.61. The company's market capitalization stands at $1.15 billion [3]. - The stock's beta is 1.14, indicating it is slightly more volatile than the market, and it has a trading volume of 361,576 shares, suggesting active trading [5]. Insider Activity - Insider Derek Maetzold sold 509 shares on December 17th at an average price of $40.04, totaling $20,380, which reduced his holdings by 1.46%, leaving him with 34,360 shares valued at approximately $1.38 million [2][6]. Financial Health - Castle Biosciences exhibits strong liquidity with a quick ratio of 6.31 and a current ratio of 6.47, indicating the ability to cover short-term liabilities easily. The company also has a minimal debt-to-equity ratio of 0.02, reflecting low financial leverage [4][6].

Core Insights - Quest Diagnostics will present its strategy, performance, and market trends at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 [1] - The presentation will be available via live webcast and archived for later access [2] Company Overview - Quest Diagnostics is a leading provider of diagnostic information services, serving one in three adult Americans and half of the physicians and hospitals in the U.S. [3] - The company aims to improve health outcomes through diagnostic insights derived from a large database of clinical lab results [3] - With over 55,000 employees, Quest Diagnostics focuses on transforming lives and creating a healthier world through its services [3]

Company forms a new subsidiary, Avalon Quantum AI, LLC, in connection with the acquisition Acquisition expected to resolve Nasdaq minimum stockholders’ equity deficiency RPM Interactive has developed a fully automated, generative AI powered SaaS platform for creating short-form video content FREEHOLD, N.J., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that it has acquired RPM Inter ...

Core Insights - Lumexa Imaging is making its public debut by raising $462.5 million in its IPO [1] - The company operates 184 diagnostic centers across 13 states [1] - Lumexa Imaging will begin trading on the Nasdaq under the ticker LMRI [1] - CEO Caitlin Zulla discussed the company's debut on Bloomberg Open Interest [1]

FREEHOLD, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced a series of Q3 2025 advancements for KetoAir™, including expanded deployment, the launch of a first-responder metabolic health program, and entry into an international market. Key Highlights Launched Holistic Health Reset Program with First Responders in NevadaIn August 2025, Avalon, together with Saga Health and Specialty ...

Core Points - Oracle Corporation has elected Stephen Rusckowski to its Board of Directors, increasing the board size to 14 members, effective November 18, 2025 [1][4] - Rusckowski has extensive experience in healthcare and technology, having served as CEO of Quest Diagnostics and Philips Healthcare, which is expected to provide valuable insights for Oracle Health [2][3] - The board members serve one-year terms, with the next election scheduled for November 2026 [4] Company Background - Oracle offers integrated applications and secure, autonomous infrastructure in the Oracle Cloud, positioning itself as a leader in cloud computing [5]